ArticleFrontiers in oncology2025
Targeting GJB4 to inhibit tumor growth and induce ferroptosis in pancreatic cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GJB2 drives LUAD progression in part via cAMP-mediated M2 macrophage polarization through the PKA-CREB pathway.Respiratory research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer (PC) is a highly malignant type of cancer characterized by poor prognosis and high mortality rate. The role of gap junction protein beta 4 (GJB4) in PC has been scarcely reported. Therefore, the aim of this study was to investigate the function of GJB4 in PC cells and its potential as a therapeutic target. Methods: The expression of GJB4 in patients with PC was examined using data from The Cancer Genome Atlas (TCGA), The Human Protein Atlas, Gene Expression Omnibus (GEO), Tumor Immune Estimation Resource (TIMER), microRNA Target Prediction Database (miRDB), and Encyclopedia of RNA Interactomes (ENCORI). A short hairpin-RNA lentiviral vector was employed to downregulate GJB4 in PC cells. The effects on tumor cell proliferation, invasion, and metastasis were assessed using cell proliferation assays, Transwell migration assays, wound healing assays, and subcutaneous xenograft models. Bioinformatics analysis was conducted to explore the function of GJB4 in PC cells. Changes in ferroptosis in PC cells following GJB4 downregulation were detected by immunofluorescence staining, transmission electron microscopy, and western blotting. Results: GJB4 expression was found to be upregulated in PC tissues and positively correlated with patient survival. The expression of GJB4 was related to immune cell infiltration, tumor mutational burden expression and miRNAs. Downregulation of GJB4 inhibited the proliferation, metastasis, and invasion of PC cells, as well as tumor growth in nude mouse subcutaneous xenografts. Knockdown of GJB4 in PC cells disrupted oxidative and iron ion balance, and promoted ferroptosis, thereby inhibiting tumorigenic properties. Conclusion: The findings of this study indicate that downregulation of GJB4 may suppress tumor characteristics by promoting ferroptosis in PC cells. Therefore, GJB4 may be a promising therapeutic target for the treatment of PC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.